Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
As the global economy mends, the 2021 growth of Human Cytomegalovirus Envelope Glycoprotein B will have significant change from previous year. According to our researcher latest study, the global Human Cytomegalovirus Envelope Glycoprotein B market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Human Cytomegalovirus Envelope Glycoprotein B market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Human Cytomegalovirus Envelope Glycoprotein B market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Human Cytomegalovirus Envelope Glycoprotein B market, reaching US$ million by the year 2028. As for the Europe Human Cytomegalovirus Envelope Glycoprotein B landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Human Cytomegalovirus Envelope Glycoprotein B players cover Astellas Pharma Inc., Trellis Bioscience, Inc., Vakzine Projekt Management GmbH, and VBI Vaccine Inc, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Cytomegalovirus Envelope Glycoprotein B market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
CSJ-148
CyMVectin
TRL-345
PPCM
Cytomegalovirus Vaccine
Others
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Infectious Disease
Oncology
Women's Health
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Astellas Pharma Inc.
Trellis Bioscience, Inc.
Vakzine Projekt Management GmbH
VBI Vaccine Inc
Vical Incorporated
The United States Human Cytomegalovirus Envelope Glycoprotein B market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Human Cytomegalovirus Envelope Glycoprotein B market, reaching US$ million by the year 2028. As for the Europe Human Cytomegalovirus Envelope Glycoprotein B landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Human Cytomegalovirus Envelope Glycoprotein B players cover Astellas Pharma Inc., Trellis Bioscience, Inc., Vakzine Projekt Management GmbH, and VBI Vaccine Inc, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Cytomegalovirus Envelope Glycoprotein B market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
CSJ-148
CyMVectin
TRL-345
PPCM
Cytomegalovirus Vaccine
Others
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Infectious Disease
Oncology
Women's Health
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Astellas Pharma Inc.
Trellis Bioscience, Inc.
Vakzine Projekt Management GmbH
VBI Vaccine Inc
Vical Incorporated
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
